Harry Holliday, MD
Pulmonary Disease · Starkville, MSNPI 1053335372
Payments from drug & device makers
Across 109 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$352
- Mylan Specialty L.p.$338
- Inspire Medical Systems, Inc.$242
- Harmony Biosciences LLC$158
- AstraZeneca$115
- Electromed, Inc.$80
- plus $602 from 18 others
What the payments were for
- Food & beverage$1,87299%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 26 | $352 |
| Mylan Specialty L.p. | 27 | $338 |
| Inspire Medical Systems, Inc. | 3 | $242 |
| Harmony Biosciences LLC | 9 | $158 |
| AstraZeneca | 7 | $115 |
| Electromed, Inc. | 4 | $80 |
| Grifols USA, LLC | 4 | $73 |
| Lilly USA, LLC | 4 | $64 |
| Jazz Pharmaceuticals Inc. | 2 | $60 |
| Boehringer Ingelheim | 3 | $56 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| Insmed, Inc. | 3 | $43 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| AbbVie | 2 | $28 |
| Merck | 1 | $28 |
| Sanofi | 1 | $26 |
| Philips North America LLC | 1 | $23 |
| Verona Pharma, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Medtronic | 1 | $17 |
| Bayer | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$1,888 in reported general payments places this provider in the 30th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $189,430 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 223 | $187,365 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 107 | $81,464 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $60,094 |
| Dupixent SyringeDupilumab | 13 | $57,382 |
| Spiriva RespimatTiotropium Bromide | 47 | $31,032 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $16,535 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $15,919 |
| Bosentan | 12 | $13,958 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $13,920 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 318 | $10,628 |
| Incruse ElliptaUmeclidinium Bromide | 21 | $6,986 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,551 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $5,433 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $5,095 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $352 | $259,475383 claims |
| Grifols USA, LLCProlastin C | $73 | $189,43013 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $115 | $107,164192 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $56 | $61,48792 claims |
| MerckDulera | $28 | $4,79216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Starkville
- Cameron HuxfordStarkville$155K
- Ravali TarigopulaStarkville$5K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
- Bobby TullosGulfport$361K
- Michal SenitkoJackson$355K
- Andrew WilhelmJackson$164K
- L AldredHattiesburg$76K
- Maria RappaiJackson$45K
- Raymond PortisJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.